Jens Holmberg
Lund University
19 Papers
185 Citations
Jens Holmberg is an academic researcher from Lund University. The author has contributed to research in topics: Arthritis & Rheumatoid arthritis. The author has an hindex of 13, co-authored 19 publications. Previous affiliations of Jens Holmberg include Karolinska Institutet.
Chat about Author
Papers
Positional identification of Ncf1 as a gene that regulates arthritis severity in rats.
TL;DR: It is found that a naturally occurring polymorphism of Ncf1 (encoding neutrophil cytosolic factor 1, a component of the NADPH oxidase complex) regulates arthritis severity and is associated with a new autoimmune mechanism leading to severe destructive arthritis, notably similar to rheumatoid arthritis in humans.
413
Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in the Ncf1 gene
Malin Hultqvist,Peter Olofsson,Jens Holmberg,B. Thomas Bäckström,Jesper Tordsson,Rikard Holmdahl +5 more
TL;DR: Ncf1, a gene important for oxidative burst, regulates the susceptibility and severity of both arthritis and encephalomyelitis and modulates, directly or indirectly, the level of T cell-dependent autoimmune responses.
380
Arthritis induced in rats with non-immunogenic adjuvants as models for rheumatoid arthritis
Rikard Holmdahl,Johnny C. Lorentzen,Johnny C. Lorentzen,Shemin Lu,Peter Olofsson,Lena Wester,Jens Holmberg,Ulf Pettersson +7 more
TL;DR: In this article, the authors proposed a disease-oriented genetic approach to unravel the mechanisms behind adjuvant-induced rheumatoid arthritis in rats, and found several loci that control onset of arthritis, severity and chronicity of the disease.
A New Arthritis Therapy with Oxidative Burst Inducers
TL;DR: Treatment of arthritis with ROS-promoting substances such as phytol targets a newly discovered pathway leading to autoimmune inflammatory disease and introduces a novel class of therapeutics for treatment of RA and possibly other chronic inflammatory diseases.
Pristane, a Non-Antigenic Adjuvant, Induces MHC Class II-Restricted, Arthritogenic T Cells in the Rat
TL;DR: The data suggest that the in vivo administration of a non-antigenic adjuvant, like pristane, activates CD4+ αβT cells that are MHC class II restricted and arthritogenic.
86